Figure S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Endocrine therapy response improves with precision treatment in HR+/HER2- breast cancer.
• Key findings suggest subtype-specific pathways influence treatment outcomes for various patient groups.
• Analysis of pathways associated with therapy response across four breast cancer subtypes indicates tailored approaches are beneficial.
• Refined targeting in treatment may help overcome limitations of traditional broad-spectrum therapies.